Should You Buy American Healthcare REIT Inc (AHR) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
46.910
1 Day change
-0.66%
52 Week Range
51.020
Analysis Updated At
2026/01/29
Based on the provided data, American Healthcare REIT Inc (AHR) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has positive long-term demand fundamentals and analyst support, the recent financial performance, insider selling trends, and lack of strong trading signals suggest a cautious approach. Holding the stock or waiting for further clarity on financial and market trends may be more prudent.
Technical Analysis
The MACD is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 55.39, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 47.068, with resistance at 48.378 and support at 45.757.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
8
Buy
3
Positive Catalysts
Analysts have a generally positive outlook, with multiple Buy and Outperform ratings and price targets ranging from $52 to $
The company is well-positioned in the healthcare REIT sector, benefiting from favorable demographic trends and demand fundamentals.
Revenue increased by 9.38% YoY in Q3 2025.
Neutral/Negative Catalysts
Insider selling has increased significantly, up 148.13% over the last month, which could indicate a lack of confidence from insiders.
Net income and EPS have dropped significantly YoY, with net income down -1455.48% and EPS down -1200.00%.
The MACD and technical indicators suggest a lack of bullish momentum.
No significant hedge fund activity or congress trading data to support a strong buy case.
Financial Performance
In Q3 2025, revenue increased by 9.38% YoY to $572.94M, showing growth in top-line performance. However, net income dropped drastically by -1455.48% YoY to $55.93M, and EPS fell by -1200.00% YoY to 0.33, indicating significant profitability challenges. Gross margin slightly improved by 0.05% YoY to 19.13.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts are generally positive on AHR, with multiple Buy and Outperform ratings. Recent price targets range from $52 to $60, reflecting optimism about the company's growth potential in the healthcare REIT sector. However, some analysts note that REITs are not particularly cheap, and the sector faces mixed sentiment overall.
Wall Street analysts forecast AHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AHR is 55.36 USD with a low forecast of 47 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast AHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AHR is 55.36 USD with a low forecast of 47 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 47.220
Low
47
Averages
55.36
High
60
Current: 47.220
Low
47
Averages
55.36
High
60
BMO Capital
Juan Sanabria
Outperform
initiated
$55
AI Analysis
2026-01-29
New
Reason
BMO Capital
Juan Sanabria
Price Target
$55
AI Analysis
2026-01-29
New
initiated
Outperform
Reason
BMO Capital analyst Juan Sanabria initiated coverage of American Healthcare REIT with an Outperform rating and $55 price target. The company is well positioned to continue to deliver leading earnings growth driven by its Trilogy and senior housing exposure, the analyst tells investors in a research note. BMO believes American Healthcare has "robust" demand/supply fundamentals that are expected to accelerate.
Truist
Michael Lewis
Buy
downgrade
$53 -> $52
2026-01-20
Reason
Truist
Michael Lewis
Price Target
$53 -> $52
2026-01-20
downgrade
Buy
Reason
Truist analyst Michael Lewis lowered the firm's price target on American Healthcare REIT to $52 from $53 and keeps a Buy rating on the shares. The firm adjusted ratings and targets in the real estate investment trust group as part of its 2026 outlook. Truist remains Neutral on REITs for 2026, saying fundamentals are improving as new supply slows and demand appears steady for high-quality assets. However, the stocks do not appear particularly cheap, the analyst tells investors in a research note. Truist is relatively bullish on healthcare, industrial, strip retail, gaming and lodging REITs, neutral on manufactured housing, multifamily, self-storage and triple net, and relatively cautious on mall and office.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AHR
